Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LIMN

Liminatus Pharma Inc

Dec 08 • 04:00PM ET

0.8640

+0.0250 2.98 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	79.47%	Shs Outstand	27.06M	Perf Week	-10.49%
Market Cap	23.39M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.56M	Perf Month	-32.50%
Enterprise Value	24.11M	PEG	-	EPS next Q	-	Inst Own	0.97%	Short Float	4.79%	Perf Quarter	-64.73%
Income	-2.58M	P/S	-	EPS this Y	-	Inst Trans	8.18%	Short Ratio	0.39	Perf Half Y	-96.68%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-116.93%	Short Interest	0.27M	Perf YTD	-92.30%
Book/sh	-0.06	P/C	32.48	EPS next 5Y	-	ROE	-	52W High	33.66 -97.43%	Perf Year	-91.86%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.61 40.72%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.90% 14.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.82%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.35	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.42	EPS Q/Q	24.67%	SMA20	-13.52%	Beta	0.39	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-30.57%	Rel Volume	0.31	Prev Close	0.84
Employees	3	LT Debt/Eq	-	Earnings	-	SMA200	-86.56%	Avg Volume	677.11K	Price	0.86
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	209,903	Change	2.98%

Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
08:31AM	Loading…
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your FINVIZ experience